Denkert et al.26 has revealed that there is a clear relationship between the number of TILs and pCR in breast cancer treated with neoadjuvant chemotherapy, but in HR-positive/HER2-negative disease, this has translated into shorter overall survival. This evidence concerns the gene ERBB2 and breast cancer.